Table 1.
Patient Characteristics of Enrolled MuSK Myasthenia Gravis Patient
| Patient No. | Age at Onset (Years)/Sex | Disease Duration (Months) | MGFA Class Pre-RTX | Past Treatments | CD19+ B Cell Pre-RTX (%) | CD19+CD27+ B Cell Pre-RTX (%) | Follow-Up Post- RTX (Months) | RTX Induction Regimen | No. of RTX Cycles | MGFA PIS Post-RTX | Steroid Dose Reduction (%) | Current Medications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 29/F | 2 | IIb | P, Py | 15.28 | 5.88 | 29 | 375mg/m2×2 | 1 | PR | 83.3 | P |
| 2 | 37/F | 24 | IVb | P, Py, IVIG | 1.01 | NA | 23 | 375mg/m2 | 4 | I | 75 | P, Py |
| 3 | 54/F | 1 | IIIb | P, Py | 30.43 | 16.48 | 28 | 375mg/m2 | 1 | MMS | 70 | P, Py |
| 4 | 51/F | 3 | IIb | P | 19.26 | 5.08 | 28 | 375mg/m2 | 1 | CSR | 100 | - |
| 5 | 41/F | 9 | IIb | P | 10.36 | 4.00 | 26 | 375mg/m2×2 | 2 | PR | 75 | P |
| 6 | 56/F | 2 | IIIa | P | 23.44 | 13.15 | 25 | 375mg/m2×2 | 1 | PR | 83.3 | P |
| 7 | 39/F | 36 | IIIb | P, Py | NA | NA | 9 | 375mg/m2×2 | 1 | MMS | 75 | P, Py |
| 8 | 52/F | 9 | IIb | P, Py | NA | NA | 8 | 375mg/m2×2 | 1 | MMS | 50 | P, Py |
Notes: “Post treatment” refer to the last clinic visit date. The follow-up period begins at the initiation of rituximab.
Abbreviations: MGFA, Myasthenia Gravis Foundation of America; MuSK, muscle-specific tyrosine kinase; RTX, rituximab; MM, minimal manifestation; I, improvement; CSR, complete stable remission; PR, pharmacological remission; IVIG, intravenous immunoglobulin; P, prednisone; Py, pyridostigmine, NA, not available.